Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results
/in International Publications, Malignant Melanoma /von 2005-03-18 / Vaccine 2005 Mar;23(17-18):2367-73Melanoma immunotherapy: past, present, and future
/in International Publications, Malignant Melanoma /von 2005-01-01 / Curr. Pharm. Des. 2005;11(27):3461-73Comparison of the anti-tumor effects of various whole-body hyperthermia protocols: correlation with HSP 70 expression and composition of splenic lymphocytes
/in Hyperthermia, International Publications, Malignant Melanoma /von 2005-01-01 / Immunol. Invest. 2005;34(3):245-58Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis
/in International Publications, Malignant Melanoma /von 2004-10-01 / Cancer Biother. Radiopharm. 2004 Oct;19(5):658-65The impact of surgery and mild hyperthermia on tumor response and angioneogenesis of malignant melanoma in a rat perfusion model
/in Hyperthermia, International Publications, Malignant Melanoma /von 2004-08-23 / BMC Cancer 2004 Aug;4:53[Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene]
/in International Publications, Malignant Melanoma /von 2004-08-01 / Ai Zheng 2004 Aug;23(8):910-3Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients
/in International Publications, Malignant Melanoma /von 2004-07-10 / Int. J. Cancer 2004 Jul;110(5):730-40Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2003-10-15 / J. Clin. Oncol. 2003 Oct;21(20):3826-35Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2003-10-01 / Melanoma Res. 2003 Oct;13(5):521-30
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
- Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
- Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy